Review
Biology
Levon Halabelian, Dalia Barsyte-Lovejoy
Summary: PRMT7, a member of the PRMT family, plays a critical role in regulating protein-protein and protein-nucleic acid interactions through arginine methylation. Its activity is linked to various biological functions such as stress response, RNA biology, gene expression regulation, and cancer-associated phenotypes. Studies on PRMT7 deficiency have revealed its roles in muscle cell physiology, B cell biology, immunity, and brain function, highlighting its importance as a cellular regulator of arginine methylation in health and disease.
Article
Oncology
Laura Oksa, Artturi Makinen, Atte Nikkila, Noora Hyvarinen, Saara Laukkanen, Anne Rokka, Pekka Haapaniemi, Masafumi Seki, Junko Takita, Otto Kauko, Merja Heinaniemi, Olli Lohi
Summary: Approximately 15-25% of acute lymphoblastic leukemias (ALL) originate from T-lineage cells, with T-ALL having a less favorable prognosis compared to B-ALL. High expression of PRMT7 was identified in T-ALL cells, and genetic deletion of PRMT7 decreased colony formation and altered arginine monomethylation patterns in protein complexes associated with RNA and DNA processing. Disruption of arginine monomethylation patterns was observed in proteins linked to T-ALL pathogenesis, such as RUNX1, leading to deregulated target gene expression. These findings suggest that PRMT7 plays a crucial role in T-ALL pathogenesis.
Article
Cell Biology
Nivine Srour, Oscar D. Villarreal, Swanand Hardikar, Zhenbao Yu, Samuel Preston, Wilson H. Miller, Magdelena M. Szewczyk, Dalia Barsyte-Lovejoy, Han Xu, Taiping Chen, Sonia Del Rincon, Stephane Richard
Summary: Combining PRMT7 inhibition with ICI therapy induces a strong anti-tumor T cell immunity and restrains tumor growth in vivo by increasing immune cell infiltration.
Article
Multidisciplinary Sciences
Ting Shen, Ting Ni, Jiaxuan Chen, Haitao Chen, Xiaopin Ma, Guangwen Cao, Tianzhi Wu, Haisheng Xie, Bin Zhou, Gang Wei, Hexige Saiyin, Suqin Shen, Peng Yu, Qianyi Xiao, Hui Liu, Yuzheng Gao, Xidai Long, Jianhua Yin, Yanfang Guo, Jiaxue Wu, Gong-Hong Wei, Jinlin Hou, De-Ke Jiang
Summary: Most cancer-causing variations are found in gene regulatory elements, such as enhancers. However, enhancer variants predisposing to hepatocellular carcinoma (HCC) have not been reported before. In this study, a genome-wide survey was conducted in 11,958 individuals to identify HCC-susceptible enhancer variants, and rs73613962 within the intronic region of PRMT7 was discovered as a susceptibility locus for HCC. The functional activity of this region as an enhancer was confirmed through experimental assays. The upregulation of PRMT7, which is regulated by this enhancer region through the binding of the transcription factor HNF4A, contributes to HCC-related phenotypes both in vitro and in vivo. This finding sheds light on the pathogenesis of HCC and may provide new opportunities for its prevention and treatment.
NATURE COMMUNICATIONS
(2022)
Article
Biochemistry & Molecular Biology
Ahyeon Jeong, Yena Cho, Minkyeong Cho, Gyu-Un Bae, Dae-Geun Song, Su-Nam Kim, Yong Kee Kim
Summary: PRMT7 is a critical regulator of cell growth and DNA damage response, and its inhibition can cause cell cycle arrest and disruption of DNA repair pathways. Combination with doxorubicin enhances its cytotoxic effect on cells.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Xuemei Wang, Wenfang Xu, Chongyang Zhu, Yu Cheng, Jiemin Qi
Summary: PRMT7 is expressed at low levels in gastric cancer tissues and is associated with clinical characteristics. Functionally, PRMT7 inhibits proliferation and migration of gastric cancer cells. Mechanistically, PRMT7 suppresses PI3K/AKT signaling pathway activation by regulating PTEN. These findings suggest that PRMT7 may be a promising therapeutic target for gastric cancer.
Article
Cell Biology
Jerome Levallet, Tiphaine Biojout, Celine Bazille, Manon Douyere, Fatemeh Dubois, Dimitri Leite Ferreira, Jasmine Taylor, Sylvain Teulier, Jerome Toutain, Nicolas Elie, Myriam Bernaudin, Samuel Valable, Emmanuel Bergot, Guenaelle Levallet
Summary: The over-activation of NDR2 kinase under hypoxia conditions promotes brain metastasis formation in NSCLC. NDR2 expression serves as a reliable indicator for predicting the risk of metastasis in NSCLC patients.
CELL DEATH & DISEASE
(2023)
Article
Multidisciplinary Sciences
Guozhen Gao, Simone Hausmann, Natasha M. Flores, Ana Morales Benitez, Jianjun Shen, Xiaojie Yang, Maria D. Person, Sitaram Gayatri, Donghang Cheng, Yue Lu, Bin Liu, Pawel K. Mazur, Mark T. Bedford
Summary: CARM1 promotes transcription by modifying histones and chromatin bound proteins, and NFIB utilizes CARM1 as a coactivator. In small cell lung cancer, both CARM1 and methylated NFIB are critical for rapid tumor growth.
NATURE COMMUNICATIONS
(2023)
Article
Chemistry, Multidisciplinary
Wei-Wei Fan, Tian Xu, Jia Gao, Han-Yu Zhang, Yan Li, Duo-Duo Hu, Shuaixin Gao, Jia-Hai Zhang, Xing Liu, Dan Liu, Pi-Long Li, Catherine C. L. Wong, Xue-Biao Yao, Yun-Yu Shi, Zhen-Ye Yang, Xi-Sheng Wang, Ke Ruan
Summary: A bivalent inhibitor was discovered to block the multivalent interactions among stress granules and inhibit their growth in cells.
CHEMICAL COMMUNICATIONS
(2023)
Article
Cell Biology
Chang Liu, Waiyi Zou, Danian Nie, Shuyi Li, Chen Duan, Min Zhou, Peilong Lai, Shengyong Yang, Sen Ji, Yangqiu Li, Mei Mei, Shilai Bao, Yanli Jin, Jingxuan Pan
Summary: This study investigates the role of PRMT family member PRMT7 in the maintenance of leukemia stem cells (LSCs) in chronic myeloid leukemia (CML). The research shows that targeting PRMT7 delays leukemia development and impairs self-renewal of LSCs without affecting normal hematopoiesis. Mechanistically, loss of PRMT7 leads to reprogramming of glycine metabolism, generating methylglyoxal which is detrimental to LSCs. These findings suggest PRMT7 as a potential therapeutic target for eradicating LSCs in CML.
Article
Cell Biology
Qianzhi Chen, Qingyi Hu, Yan Chen, Na Shen, Ning Zhang, Anshu Li, Lei Li, Junjun Li
Summary: This study highlights the crucial role of PRMT6-mediated STAT3 R729me2a in breast cancer metastasis, revealing that PRMT6 positively regulates breast cancer metastasis through its effect on STAT3. Furthermore, the study identifies STAT3 R729me2a as a robust prognostic marker for predicting overall survival time in breast cancer patients. Additionally, the PRMT6 inhibitor EPZ020411 demonstrates significant potential in curbing breast cancer metastasis.
CELL DEATH & DISEASE
(2023)
Article
Chemistry, Medicinal
Alessandra Feoli, Giulia Iannelli, Alessandra Cipriano, Ciro Milite, Lei Shen, Zhihao Wang, Andrea Hadjikyriacou, Troy L. Lowe, Cyrus Safaeipour, Monica Viviano, Giuliana Sarno, Elva Morretta, Maria Chiara Monti, Yanzhong Yang, Steven G. Clarke, Sandro Cosconati, Sabrina Castellano, Gianluca Sbardella
Summary: PRMT7 and PRMT9 have been identified as important therapeutic targets, but their biological roles, functions, and structural requirements are still unclear. This study discovered a potent PRMT7/9 inhibitor and revealed its binding mode to the two enzymes. The inhibition of PRMT activity in cells was confirmed, and an effective AlphaLISA assay was developed for screening small molecule inhibitors of PRMT9.
JOURNAL OF MEDICINAL CHEMISTRY
(2023)
Article
Biochemistry & Molecular Biology
Danyang Chen, Siwen Fan, Jun Wang, Yanqing Liang, Pan Li, Xinwu Lv, Yanqin Sun, Qian Wang, Hao Liu, Chuantao Zhang, Yanmei Yi
Summary: Cancerous inhibitor of protein phosphatase 2A (Cip2a) is an oncoprotein that plays a crucial role in promoting tumor aggressiveness in non-small cell lung cancer (NSCLC). The study found that elevated Cip2a expression in NSCLC is associated with poor prognosis. Knockdown of Cip2a significantly inhibited cell proliferation, invasion, and metastasis of NSCLC both in vitro and in vivo. Furthermore, it was discovered that Cip2a promotes tumor progression by inducing arginine biosynthesis and its knockdown increases sensitivity to arginine deprivation and mTOR inhibition. In addition, p53 mutants in NSCLC cells increase Cip2a expression by inhibiting wild-type p53 activity. The findings provide valuable insights into the mechanisms of Cip2a in NSCLC and suggest it as a potential therapeutic target.
MOLECULAR CARCINOGENESIS
(2023)
Article
Biochemistry & Molecular Biology
Junji Zhu, Xiong Li, Xiaolian Cai, Huangyuan Zha, Ziwen Zhou, Xueyi Sun, Fangjing Rong, Jinghua Tang, Chunchun Zhu, Xing Liu, Sijia Fan, Jing Wang, Qian Liao, Gang Ouyang, Wuhan Xiao
Summary: PRMT7 regulates MAVS-mediated antiviral response through arginine monomethylation, negatively regulating MAVS activation and ensuring timely antiviral defense activation. Modulation of PRMT7 activity provides insights into mechanisms controlling innate immune response.
Article
Oncology
Shuangjie Liu, Zhuonan Liu, Chiyuan Piao, Zhe Zhang, Chuize Kong, Lei Yin, Xi Liu
Summary: The study reveals PRMT5 as a therapeutic target for bladder cancer and identifies FKA, extracted from the kava plant, as an inhibitor of PRMT5 for the treatment of bladder cancer.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2022)
Article
Biology
Yuantao Cui, Min Ding, Shangwen Dong, Yuanguo Wang, Peng Zhang
OPEN LIFE SCIENCES
(2016)
Article
Medicine, Research & Experimental
Yuantao Cui, Yuan Xue, Shangwen Dong, Peng Zhang
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH
(2017)
Article
Oncology
Yaowen Zhang, Shangwen Dong, Ruiping Xu, Yanping Yang, Zhiyong Zheng, Xiaojing Wang, Runchuan Ren, Ronggang Sun, Ming Li, Haijun Yang, Yuting Huang, Fuyou Zhou, Anping Zheng
Article
Oncology
Yang Lu, Fanjie Meng, Yang Yang, Lan Li, Donghao Wang, Yuantao Cui, Shangwen Dong, Wanhua Wang
Article
Oncology
Shangwen Dong, Miao Qi, Ying Wang, Liming Chen, James Crofton Weaver, Steven Antony Krilis, Bill Giannakopoulos
Article
Oncology
Ran Liu, Huiting Wei, Peng Gao, Hu Yu, Ke Wang, Zheng Fu, Baohui Ju, Meng Zhao, Shangwen Dong, Zhijun Li, Yifeng He, Yuting Huang, Zhi Yao
Article
Multidisciplinary Sciences
Fatima El-Assaad, Miao Qi, Alice Kizny Gordon, Jian Qi, Shangwen Dong, Freda Passam, James Crofton Weaver, Bill Giannakopoulos, Steven Anthony Krilis
SCIENTIFIC REPORTS
(2017)
Review
Respiratory System
Xiongfei Li, Renwang Liu, Tao Shi, Shangwen Dong, Fan Ren, Fan Yang, Dian Ren, Haiyang Fan, Sen Wei, Gang Chen, Jun Chen, Song Xu
JOURNAL OF THORACIC DISEASE
(2017)
Article
Health Care Sciences & Services
Yang Lyu, Yang Yang, Xin Li, Min Peng, Xin He, Peng Zhang, Shangwen Dong, Wanhua Wang, Donghao Wang
THERAPEUTICS AND CLINICAL RISK MANAGEMENT
(2018)
Article
Oncology
Yaowen Zhang, Huitao Wang, Xiao Huang, Qiang Zhang, Runchuan Ren, Ronggang Sun, Zhiyong Zheng, Shangwen Dong, Anping Zheng
Article
Emergency Medicine
Yang Lu, Yang Yang, Xin He, Shangwen Dong, Wanhua Wang, Donghao Wang, Peng Zhang
AMERICAN JOURNAL OF EMERGENCY MEDICINE
(2017)
Article
Medicine, Research & Experimental
Min Ding, Lihong Liu, Liyun Zhang, Yuantao Cui, Meijun Wang, Penghua Wang, Qian Yu, Tingwei Zhang, Shangwen Dong, Demin Yu, Chunjun Li
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE
(2017)
Meeting Abstract
Oncology
Kunlong Tang, Yuting Huang, Shangwen Dong, Peng Gao
Meeting Abstract
Oncology
Yuting Huang, Peng Gao, Yifeng He, Yuchi Ma, Shangwen Dong, Zhijun Li